Adma Biologics (ADMA) Receivables (2012 - 2025)

Adma Biologics has reported Receivables for 14 years, with the latest figure at $158.4 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables rose 216.86% year-over-year to $158.4 million; the trailing twelve-month figure through Dec 2025 stood at $158.4 million (up 216.86% YoY), and the FY2025 full-year result was $158.4 million, up 216.86% from the prior year.
• Receivables for Q4 2025 stood at $158.4 million, up from $137.7 million in the prior quarter.
• The five-year high for Receivables was $158.4 million in Q4 2025, with the low at $15.4 million in Q1 2021.
• Historically, Receivables has averaged $48.8 million across 5 years, with a median of $29.3 million in 2021.
• Annual changes were most pronounced in 2022 — Receivables sank 45.74% — and 2025, when it surged 264.38%.
• Adma Biologics' Receivables stood at $28.6 million in 2021, then slumped by 45.74% to $15.5 million in 2022, then surged by 76.85% to $27.4 million in 2023, then soared by 82.34% to $50.0 million in 2024, then soared by 216.86% to $158.4 million in 2025.
• The last three Receivables figures came in at $158.4 million (Q4 2025), $137.7 million (Q3 2025), and $109.7 million (Q2 2025), per Business Quant data.